Michael Goldberg, Surge Therapeutics founder and CEO

Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Weeks ago, Surge Ther­a­peu­tics marked what CEO Michael Gold­berg hopes will go down in his­to­ry as a turn­ing point in can­cer care: the first time a pa­tient re­ceived an im­munother­a­py, in the form of a hy­dro­gel, at the site of their tu­mor dur­ing surgery.

Now, the Cam­bridge, MA-based biotech has raised $32 mil­lion in a Se­ries B to fund that tri­al while bring­ing to the clin­ic two more can­di­dates with the same ap­proach, which it calls in­tra­op­er­a­tive im­munother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.